Physician profile
Casey Lynn Bourque
NPI 1508482902
$6,267.63
in general payments reported to CMS, 2019-2025
29 companies · $4,431 in 2025
The $4,431 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $846 · 2022: $674 · 2023: $274 · 2024: $41.94 · 2025: $4,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,520 · Food and Beverage: $1,139 · Travel and Lodging: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,520.00 |
| Food and Beverage | $1,138.90 |
| Travel and Lodging | $1,088.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,295.13 | 2023-2025 | |
| Abbvie INC. | $575.14 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $252.94 | 2022-2023 | Farxiga |
| Revance Therapeutics, INC. | $244.37 | 2025 | Daxxify |
| Novo Nordisk INC | $187.55 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.93 | 2021 | |
| Lilly USA, LLC | $82.50 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.72 | 2021-2022 | |
| Boston Scientific Corporation | $52.20 | 2021-2022 | |
| Allergan, INC. | $49.05 | 2021 | |
| Janssen Pharmaceuticals, INC | $43.53 | 2022 | |
| Amgen INC. | $42.98 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $25.99 | 2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $24.74 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $19.51 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $18.84 | 2021 | |
| Astellas Pharma US INC | $18.64 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.81 | 2022 | |
| Organon LLC | $16.73 | 2021 | |
| Alfasigma USA, INC. | $16.58 | 2022 | |
| Phadia US INC. | $15.95 | 2024 | Immunocap |
| Bardy Diagnostics, INC. | $14.83 | 2022 | |
| Merck Sharp & Dohme LLC | $13.67 | 2021 | |
| Seqirus USA INC | $13.58 | 2021 | |
| Vistapharm, INC. | $13.53 | 2021 | |
| Currax Pharmaceuticals LLC | $13.42 | 2022 | |
| Hologic Sales and Service, LLC | $13.13 | 2021 | |
| Glaxosmithkline, LLC. | $12.50 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Bourque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.